Abzena’s (ABZA) Buy Rating Reaffirmed at Numis Securities
Numis Securities restated their buy rating on shares of Abzena (LON:ABZA) in a report issued on Monday. Numis Securities currently has a GBX 62 ($0.89) price objective on the stock, down from their prior price objective of GBX 80 ($1.15).
Separately, Peel Hunt reaffirmed a buy rating and set a GBX 42 ($0.60) price target on shares of Abzena in a research report on Tuesday, April 10th.
LON:ABZA opened at GBX 18.06 ($0.26) on Monday. Abzena has a 52 week low of GBX 24.50 ($0.35) and a 52 week high of GBX 53 ($0.76).
Abzena plc engages in the provision of services and technologies for the development and commercialization of biopharmaceutical products in North America, Europe, the United Kingdom, and internationally. It provides antibody drug conjugate linker, antibody humanization, and protein deimmunisation technologies and solutions, which include phage display, Hybridoma sequencing, and developability assessment solutions for the discovery, isolation, development, and selection of antibodies; immunogenicity assessment and custom assays, as well as Cytokine Screen, an in vitro assay to evaluate the risk of biopharmaceutical products causing cytokine release syndrome prior to its test in clinical trials; antibody and protein engineering solutions, which cover Ig class and isotype switching, antibody reformatting and humanization, protein deimmunisation, affinity maturation, antibody and protein production, and bioassays and bioanalytics; and antibody drug conjugates, such as cysteine and lysine conjugation solutions, as well as ThioBridge, a disulfide rebridging linker.
Receive News & Ratings for Abzena Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abzena and related companies with MarketBeat.com's FREE daily email newsletter.